IL9 and Alzheimer disease: Despite the discontinuation of omalizumab due to lack of benefit in severe AD [32], treatment with this anti-IgE mAb led to reduced IL-9 plasma levels in pediatric AD [37], contributing to evidence for the link between IL-9 and IgE isotype switching in this condition.